Ann: Phosphagenics Investor presentation - Australian Roadshow, page-2

hi Sounds good brief look.  R/EM
3
Phosphagenics is a compelling investment opportunity
Approx. $20M cash and
receivables - equating to 2.5 to 3 years burn
(Jun’15)
$2M+ annual reve
nues* from TPM
®
and Vital ET
®
with plans initiated to
increase current capacity to support in
creased sales, margin and revenue
Meaningful newsflow pl
anned over 2015/16:
Near term Ph2a clinical results expected within 6 months (oxycodone patch)
Multiple Animal Health & Nutrition trials over 2015/16
TPM
®
technology already partnered for sp
ecific dermal and injectable use
–
high interest
in future business deve
lopment opportunities
Attractive valuation: share price at
all-time low:
below asset value
Focus is on shorter-term, valu
e-adding endpoi
nts and revenue
New Management/Board with strong industry experience
“...we
believe that Phosphagenics is
substantially undervalued ... the Company’s current total
value should be A$80-100M, or 8.5c per
share...(there is) substantial
upside
...”
M.Wijma, Chief Research Analyst,
Van Leeuwenhoeck Rese
arch, September 2015